A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 148
- 试验地点
- 29
- 主要终点
- 5 year overall survival
研究概览
简要总结
The purpose of this study is to determine whether acetylsalicylic acid is effective on the recurrence and survival of colon cancer patients.
详细描述
The purpose of this study is to determine the effect of 80mg acetylsalicylic acid (given orally once daily for 5 years) on 5 year overall survival (OS) for stage II and III colon cancer patients of 45 years of age and older. Preclinical, epidemiologic and clinical evidence suggest that acetylsalicylic acid use may reduce overall cancer risk and mortality in colon cancer patients. It is a phase III double blind placebo controlled, randomized trial of adjuvant low-dose acetylsalicylic acid in colon cancer patients. Patients will be stratified at randomization by centre, age (<70 and ≥70 years) chemotherapy use (any versus none) and disease stage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 45 years and older with histologically confirmed adenocarcinoma of the colon
- •Patients must have TNM stage that is one of the following: pT3-4; N0-2 and M0, or pT1-2 and N1-2 (Union for International Cancer Control (UICC) stage II and III) (in case of >1 tumour: more advanced tumour is stage II or III)
- •Patients must have completed surgical resection (R0) (both laparoscopic and open surgery) within 12 weeks of randomization
排除标准
- •Patients with rectal cancer (defined as tumour within 15 cm from the anal verge)
- •Patients currently taking oral anti-coagulants or use of LMWH or use of DOACs
- •Patients currently taking (low-dose) acetylsalicylic acid or other anti-aggregantia for any reason
- •Patients with a history of bleeding disorders or active gastric or duodenal ulcers
- •Patients currently taking high dose systemic glucocorticoids (≥ 30 mg predniso(lo)n or equivalent)
- •Patients with (suspected) (non-) polyposis syndrome (FAP/AFAP, MAP, Lynch syndrome)
- •Patients with >100 polyps of the colon or a known hereditary syndrome of the colon in a first degree family member
- •Allergy or intolerance to salicylates
- •Patients with local or distant recurrent disease
- •Previous malignancies other than CIN or SCC with a disease free survival less than 5 years
- •Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
研究组 & 干预措施
Aspirin
Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
干预措施: acetylsalicylic acid (Drug)
Placebo
Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
干预措施: Placebo (Drug)
结局指标
主要结局
5 year overall survival
时间窗: 5 years
The time to an event for OS is defined as the time interval between the date of randomisation and the date of death.
次要结局
- Disease Free Survival(5 years)
- Time to Treatment Failure(5 years)
研究者
ethisch.comite@uza.be
Prof. dr. Marc Peeters, Diensthoofd Oncologie
University Hospital, Antwerp